CRISPR Therapeutics AG
CRSP
주식 순위
#3576
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
주가
$49.61
시가총액
$4.80B
변동 (1일)
-0.87%
변동 (1년)
-32.94%
국가
CH
거래 CRISPR Therapeutics AG (CRSP)
카테고리
Healthcare
CRISPR Therapeutics AG (CRSP)의 수익
Jun 2026 기준 수익 TTM: $-448.11M
CRISPR Therapeutics AG의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-448.11M입니다. 2024년에 회사는 $-362.67M의 수익을 올렸으며 이는 2023년의 수익 $-150.72M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
CRISPR Therapeutics AG의 수익 기록 (2014 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-448.11M | -22.47% |
| 2025 | $-577.97M | 59.37% |
| 2024 | $-362.67M | 140.62% |
| 2023 | $-150.72M | -76.83% |
| 2022 | $-650.50M | -271.40% |
| 2021 | $379.53M | -209.04% |
| 2020 | $-348.06M | -617.12% |
| 2019 | $67.31M | -140.93% |
| 2018 | $-164.43M | 146.86% |
| 2017 | $-66.61M | 193.19% |
| 2016 | $-22.72M | -12.02% |
| 2015 | $-25.82M | 276.23% |
| 2014 | $-6.86M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -1,277.15% |
US
|
|
| $-3.09B | 588.90% |
US
|
|
| $-4.02B | 796.26% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -535.31% |
NL
|
